Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpikoGen Booster for COVID-19
NCT05175625Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Dec 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SpikoGen with Placebo -> SpikoGen (2 arms). Primary endpoint: Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies at 14 days. Started Dec 2021; status: completed.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05175625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175625.